In in vivo experiments, existing studies mainly focus on the specific distribution of GITR in immune cells within the TME and the rationale for combined therapy with other ICIs such as PD-1, lacking direct clinical trials to prove whether GITR has a good inhibitory effect on HNSCC [100]. This evidence concerns the gene RPL17 and head and neck squamous cell carcinoma.